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This July issue of Clinical Cytometry B includes 11
original papers, 6 brief communications, 2 letters to the
editor and a review article dealing with cancer-related
mRNA expression analysis using a novel flow cytometry-
based assay. The flow data from Depreter et al. showed
a good correlation with the gold standard, RT-qPCR tech-
nique (1). Interestingly, Wilms’ tumor 1 (WT1) gene lev-
els were shown to be significantly higher in AML patient
samples with WT1 gene overexpression, previously
defined by RT-qPCR. Moreover, WT1 overexpression was
distinguishable between heterogeneous cell populations
and was also documented in rare leukemic stem cells
(LSC). This study also showed comparable results using
fresh, short-term and long-term cryopreserved samples,
thus allowing the analysis of RNA samples on a retro-
spective basis. The paper by Depreter et al. provides
crucial information concerning the ability to detect
single-cell or rare cell population-specific gene expression
changes in acute myeloid leukemia (AML) samples. In
both adult and pediatric AML, persistence of rare LSCs are
thought to be causative for the high relapse rates, there-
fore, an increasing need for advanced instrument analyti-
cal tools, able to elucidate coding and non-coding gene
expressions at single-cell level, has emerged, and this
study may help in clarifying this aspect (2–5).
Taking into account that the liquid biopsy is becoming
a powerful diagnostic tool in solid tumor diagnosis, it is
conceivable that this test may play a role for the detection
of cancer cells from a tumor that are circulating in the
blood and may help find cancer at an early stage. It may
also be used to help plan treatment or to find out how
well treatment is working or if cancer has come back
(6,7). Furthermore, since accumulating biological evi-
dence support the notion that current chemotherapy
drugs will not be effective for leukemic stem cells killing,
or at least has the capacity to target both the leukemic
and normal stem cell populations, new strategies are
required that specifically and preferentially kill the malig-
nant stem cell population, while sparing normal stem
cells. The possibility to detect LSC using this novel flow
cytometry-based assay may allow the identification of suit-
able drugs targeting specifically LSC (6–8).
Original articles published in this issue were related
to four main fields (1) immunophenotyping of lympho-
proliferative disorders or normal cells, (2) the detection
of a rare acquired genetic disorder Paroxysmal nocturnal
hemoglobinuria (PNH), (3) immunology science with
particular emphasis on monocytes, and (4) cell function.
In the paper by Starostka et al., a quantitative assess-
ment of informative immunophenotypic markers in
mature CD5-positive B-cell neoplasms was performed,
and data showed that this approach may increase the
diagnostic value of immunophenotyping in several
chronic lymphoproliferative disorders (9). Based on their
study, the most informative markers for the distinction
of CLL/SLL, MCL, CD51 MZL were the MFI values of
the following markers: CD79b, CD20, CD23, CD43,
CD38, CD11c, FMC7, CD200, kappa light chain, and
their combinations. CD23 and CD200 were the most dis-
criminant between CLL/SLL and MCL and CD23 plus
CD79b between CLL/SLL and CD51 MZL. However, this
quantitative marker investigation failed to accurately dis-
tinguish MCL and CD51 MZL. I, therefore, believe that
this paper highlights the data mining methods for the
analysis and selection of the most informative immuno-
phenotypic markers and may help designing a predictive
model, possibly minimizing the subjectivity of expert
based assessment (10–12).
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As far as Dr. Auat’s paper is concerned, a flow cytome-
try measurement of CD307a antigen expression in B-cell
malignancies and during normal B-cell maturation has
been investigated with the main aim to explore the diag-
nostic role played by this molecule during normal and leu-
kemic differentiation (13). The results indicate that the
flow cytometry assessment of CD307a expression could
be helpful to distinguish CLL from MCL, and the latter
from MZL. Although these results are not entirely conclu-
sive, they provide a basis for further studies in a larger
cohort of patients. Interestingly, B-lymphoblasts from
acute lymphoblastic leukemia patients exhibited minimal
expression of CD307a, displaying a similar expression pat-
tern to that of normal B-cell precursors. This study may
be considered in the construction and use of flow cyto-
metric assays for minimal residual disease detection
(14–16). The identification of novel antigenic markers to
target the neoplastic cells through engineered monoclo-
nal antibodies remains one of the main goals of the most
recent treatment modalities, and this paper may provide
valuable information in this research field (16).
The second theme covered in this issue is represented
by PNH. PNH is an acquired clonal stem cell disorder
characterized by intravascular hemolysis, deep venous
thrombosis, bone marrow failure and increased suscepti-
bility to infections. PNH is a stem cell disorder caused
by a PIG-A gene mutation (17–19). As a consequence,
blood cells completely or partially lack surface proteins
that are tethered to the membrane through the glycosyl-
phosphatidylinositol (GPI) anchor. The resulting absence
of CD55 and CD59 molecules on red cells renders them
sensitive to complement-mediated intravascular hemoly-
sis and associated hemoglobinuria. Over the last 10
years, PNH testing by flow cytometry has become a
common laboratory test in the clinical practice (20–22).
In the paper published by Blaha et al., authors tested the
monoclonal anti-CD157 antibody clone SY11B5, for high
sensitivity detection of PNH clones on the leukocyte popu-
lation (23). Results showed that this reagent fails to detect a
common polymorphic variant encoded by BST-1. The failure
of anti-CD157 antibody clone SY11B5 to detect a common
SNP can explain some CD157-negative cytometric data.
This provides crucial knowledge for laboratories performing
PNH analyses as such results can potentially lead to false-
positive PNH interpretation. Due to the rare incidence of
PNH, as well as rare genetic variations such as CD157, we
suggest that flow cytometric analysis of PNH cells must not
be based on lack of expression of just a single GPI-anchored
marker. Rather a consistent deficiency of at least two
markers on at least two different cell types is required.
In the second manuscript related to PNH, one of the
leading scientist in this field of investigation, Rob Suther-
land, compared high sensitivity 5-, 6, 7-color flow cytom-
etry analysis using Becton-Dickinson and Beckman
Coulters cytometers (24). Assessment of> 40 PNH sam-
ples showed that the FLAER-based data derive virtually
identical data to the non-FLAER results for neutrophils
(R2 5 1) and monocytes (R2 5 0.9999). Furthermore,
both Canto and Navios platforms gave rise similar data
with 7-, 6-, and 5-color versions of the assay. Interest-
ingly, analysis of non-PNH samples confirmed extremely
low background rate of PNH phenotypes (neutrophils
and monocytes) with all three approaches. In conclu-
sion, this paper describes, for the first time a series of
high-sensitivity, single tube flow assays for the simulta-
neous detection of GPI-deficient leukocyte subsets
across both 3-laser Navios and Canto technologies. The
7-color variants of these assays confirm the earlier find-
ings of Marinov et al. that FLAER is not an absolute
requirement for high-sensitivity flow assays to detect
PNH clones in PNH and related diseases (25). These
results may be regarded as a practice changing approach
(20–22,26).
Due to its high sensitivity, Lindemann et al. focused
on the role played by the flow cytometry crossmatch
(FCXM) for identifying an optimal living donor in kidney
transplantation (27). In particular, the effect of ABO
incompatibility on T cell flow cytometry crossmatch has
been investigated, allowing authors to conclude that
ABO incompatibility was associated with higher T-FCXM
responses, especially in recipients with blood group O.
This finding has major impact on the interpretation of
flow crossmatch results. Based on these data, authors
have postulated that current cut-off values need to be
reassessed in the ABO incompatible setting (28).
Regarding Cecilia Langenskiold’s investigation, authors
established a flow cytometry antibody panel that can be
used to determine granulocytes, monocytes and lympho-
cyte subset concentrations in fresh and frozen whole
blood using TruCount technology (29). Using this
method whole-blood samples can be frozen using a sim-
ple preparation method, and stored long-term before
accurate determination of cell concentration. This
allows for standardized analysis of the samples at a refer-
ence laboratory in multi-center studies. This methodo-
logical improvement may be helpful in routine flow
cytometry analyses (30).
Wonner et al. investigated the effects of acute exer-
cise on monocyte subpopulations in patients with meta-
bolic syndrome (31). Results seem to demonstrate that
strenuous exercise, even if it is not sufficient for weight
loss, might exert a positive effect on vascular plaque for-
mation by removing pro-inflammatory monocytes from
the endothelium. However, as outlined by authors, this
hypothesis needs to be further investigated, since stren-
uous exercise was able to mobilize the same amount of
proinflammatory monocytes in MetS patients as in
healthy persons; it is conceivable that the elevated basal
level of these cells in MetS patients is likely to be caused
by enhanced maturation rather than chronic mobiliza-
tion. The removal of these monocytes from the endothe-
lium might be part of the beneficial effect of exercise
on vascular disease in long term studies (32,33).
Conventional data analysis of flow cytometry-based
basophil activation testing requires repetitive, labor-
intensive analysis that hampers efforts to standardize
testing for clinical applications. Using an open-source
platform, Patil et al. developed and implemented a
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programmatic approach to the analysis of the basophil
activation test (BAT) by flow cytometry. This novel
method provided a high throughput objective approach
to basophil activation analysis (34).
Del Zotto et al. published an interesting paper dealing
with a rare genetic disorder, called Fibrodysplasia Ossifi-
cans Progressiva (FOP), caused by sporadic heterozygous
mutations in ACVR, that is a gene which progressively
leads to severe heterotopic ossification (35). The periph-
eral blood mononuclear cell immunophenotyping by flow
cytometry in samples from this genetic disorder provided
evidence for monocyte DNAM1 up-regulation, as well as
significant differences in the expression profile of CXCR1
(CD181), CD62L, CXCR4 (CD184), and HL-DR molecules.
Based on the notion that DNAM1 had been previously
shown to play a pivotal role in monocyte migration
through the endothelial barrier, the increased expression
detected in patients’ monocytes might suggest a role of
this surface receptor during the early phases of FOP flare-
ups in which the activation of the immune response is
believed to represent a crucial event.
The original paper by Chutvanichkul dealt with labile
iron pool (LIP) as a parameter to monitor iron overload
and oxidative stress status in the erythrocyte population
from b-thalassemia patients (36). LIP is intracellular non-
protein bound iron that can generate oxygen radicals via
the Fenton reaction resulting in oxidative cell damage. As
a consequence, quantitative assessment of LIP may be
helpful for detecting and monitoring the toxic iron status
in iron overloaded patients. Based on authors results and
speculation, it may be hypothesized that LIP assay may
represent an alternative test to monitor the magnitude of
iron overload and its consequent oxidative stress in b-
thalassemia patients. LIP level may also be used as a
marker for a careful evaluation of the therapeutic
response to iron chelation treatment.
The investigation from the group of North Texas Uni-
versity had the main scope to study the effects of a sin-
gle high-fat meal on monocyte adhesion molecule
expression, CD36 expression and acLDL endocytosis
using image-based flow cytometry. Results showed that
consumption of a high-fat meal was associated with an
increased adhesion molecules expression in both classi-
cal and non-classical monocytes, scavenger receptors,
and propensity to form foam cells (37).
The current issue of Cytometry also includes six inter-
esting brief communications and two letters to the editor,
which all deserve a careful evaluation from the readers.
I do believe that the flow cytometry community is
today very active, productive, and vital, and in the next
years a lot of developments in this area will enrich our
knowledge in many research and clinical disciplines,
thus enhancing the use of flow cytometry as an ever-
increasing powerful diagnostic tool.
Francesco Lanza,
Hematology Institute
Romagna Stem Cell Transplantation Programme,
Ravenna 48121, Italy
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